“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 28/03/2023
EUR0.65
▲ −0.04 (−5.78%)
Market capitalisation
EUR34m
Amoéba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.
Industrials
Industrials
Director, TMT & Industrials
Fabrice Plasson
Chairman & CEO
Valérie Filiatre
Deputy general manager
Forecast net cash (€m)
5.8
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (6.2) | (15.4) | (11.8) |
| Relative | (3.0) | (21.3) | (17.0) |
| 52 week high/low | €1.2/€0.5 |
During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance used in its innovative biological fungicides. It is now looking to raise €45m to fund operations and site expansion over the next three years. €23m of the financing will be for capital expenditure, primarily on a production plant capable initially of manufacturing sufficient active substance annually to treat 100,000 hectares of crops, 200,000 hectares when extended. Management plans to have this operational by early 2025 to support product roll-out, subject to Amoéba receiving regulatory approval for individual fungicides containing the active substance in 2024.
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (4.4) | (8.0) | (49.31) | N/A | N/A |
| 2021A | 0.0 | (4.5) | (8.0) | (45.06) | N/A | N/A |
| 2022E | 0.0 | (4.5) | (7.2) | (22.87) | N/A | N/A |
| 2023E | 0.0 | (7.7) | (9.1) | (18.43) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
